No connection

Search Results

GKOS vs GRFS

GKOS
Glaukos Corporation
NEUTRAL
Price
$122.07
Market Cap
$7.14B
Sector
Healthcare
AI Confidence
80%
GRFS
Grifols, S.A.
NEUTRAL
Price
$8.21
Market Cap
$6.74B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
GKOS
--
GRFS
12.83
Forward P/E
GKOS
282.75
GRFS
5.64
P/B Ratio
GKOS
10.7
GRFS
0.92
P/S Ratio
GKOS
14.08
GRFS
0.9
EV/EBITDA
GKOS
-142.15
GRFS
9.85

Profitability

Gross Margin
GKOS
77.96%
GRFS
38.8%
Operating Margin
GKOS
-18.87%
GRFS
17.53%
Profit Margin
GKOS
-36.99%
GRFS
5.34%
ROE
GKOS
-26.38%
GRFS
6.17%
ROA
GKOS
-5.8%
GRFS
4.24%

Growth

Revenue Growth
GKOS
35.7%
GRFS
0.3%
Earnings Growth
GKOS
--
GRFS
43.5%

Financial Health

Debt/Equity
GKOS
0.16
GRFS
1.27
Current Ratio
GKOS
4.69
GRFS
2.51
Quick Ratio
GKOS
3.83
GRFS
0.84

Dividends

Dividend Yield
GKOS
--
GRFS
2.14%
Payout Ratio
GKOS
0.0%
GRFS
27.5%

AI Verdict

GKOS NEUTRAL

GKOS presents a dichotomy between strong operational growth and extreme valuation. The Piotroski F-Score of 5/9 indicates a stable financial foundation, supported by an exceptional current ratio of 4.69 and very low debt/equity (0.16). However, the company remains unprofitable with a negative profit margin of -36.99% and a staggering forward P/E of 282.75. While revenue growth is robust at 35.7%, the bearish insider sentiment and weak technical trend suggest a disconnect between analyst optimism and internal confidence.

Strengths
Strong revenue growth (35.7% YoY)
Excellent liquidity with a current ratio of 4.69
High gross margins (77.96%) indicating strong product pricing power
Risks
Extreme valuation metrics (Forward P/E 282.75, P/S 14.08)
Persistent lack of profitability over 25 consecutive quarters
Bearish insider activity with $6.41M in sales and zero buys
GRFS NEUTRAL

GRFS presents a classic 'value trap' profile: strong deterministic health (Piotroski F-Score 7/9) and deep valuation discounts (Price < Graham Number < Intrinsic Value), yet it suffers from severe market rejection. While the stock trades at a significant discount to its Graham Number of $11.36 and Intrinsic Value of $18.88, this is offset by a 0/100 technical trend and a dismal earnings track record with 0 beats in the last 4 quarters. The disconnect between strong operational health scores and poor price performance suggests systemic risks or lack of catalyst for a reversal.

Strengths
Strong Piotroski F-Score (7/9) indicating improving operational efficiency
Deep value valuation with P/B (0.92) and P/S (0.90) both under 1.0
Significant upside to Graham Number ($11.36) and Intrinsic Value ($18.88)
Risks
Severe earnings miss trend (Average surprise -27.42% over last 4 quarters)
Stagnant top-line growth (Revenue growth YoY only 0.30%)
Bearish technical momentum (Technical Trend score 0/100)

Compare Another Pair

GKOS vs GRFS: Head-to-Head Comparison

This page compares Glaukos Corporation (GKOS) and Grifols, S.A. (GRFS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile